Dossier assessment

Nirmatrelvir/ritonavir (COVID-19, without supplemental oxygen, increased risk of progressing to severe COVID-19, >= 6 years to < 18 years, >= 20 kg) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A25-158
Last updated

Report documents

  1. Extract of dossier assessment

    Nirmatrelvir/ritonavir (COVID-19, without supplemental oxygen, increased risk of progressing to severe COVID-19, >= 6 years to < 18 years, >= 20 kg) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 170 kB, DE, not accessible
  2. Dossier assessment

    Nirmatrelvir/ritonavir (COVID-19, without supplemental oxygen, increased risk of progressing to severe COVID-19, >= 6 years to < 18 years, >= 20 kg) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 596 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-158

Drug assessment at a glance

  1. Drug assessment at a glance

    Nirmatrelvir/ritonavir (COVID-19, without supplemental oxygen, increased risk of progressing to severe COVID-19, >= 6 years to < 18 years, >= 20 kg) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 234 kB, EN, not accessible

Dossier assessment

Indication:

Children and adolescents aged 6 to ≤ 17 years with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19

Result of dossier assessment:
  • Patients weighing between 20 and 40 kg: added benefit not proven
  • Patients weighing at least 40 kg: added benefit not proven

Project details

Project no.
A25-158
Commission
Commission awarded on 16.12.2025 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Immune system and infections
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A25-158

Connected Projects

  1. Dossier assessment

    Nirmatrelvir/ritonavir (COVID-19) – Benefit assessment acc. to § 35a Social Code Book V

    Project no.
    A22-64
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form